Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107
- Citation:
- Leuk Lymphoma vol 49 (7) 1274-1278
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10 CA032291, CA33601, CA101140, U10 CA077658, CA02599, CA32291, CA41287, CA03927, U10 CA031946, U10 CA033601, U10 CA101140, U10 CA041287, CA77658, CA37135, CA31946, U10 CA003927, CA07968
- Corr. Author:
- Authors:
- Meir Wetzler Kathleen A. Donohue Olatoyosi M. Odenike Eric J. Feldman David D. Hurd Richard M. Stone Peter Westerfelt Clara D. Bloomfield Richard A. Larson
- Networks:
- Study
- CALGB-10107
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Chronic myeloid leukemia, imatinib mesylate, resistance, oblimersen, bcl-2